Astellas and YASKAWA to establish JV focused on cell therapy manufacturing

Astellas stands on the forefront of healthcare change to turn innovative science into value for patients

Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro

The company uses iPS cells to develop treatments for diseases relating to the kidney

Merck invests € 300 million in new Life Science production site in South Korea

New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics

Syngene biologics facility to be operational for US, European customers from mid-year

New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day

AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability

Development services for gene and cell therapies is planned to begin first in 2025

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution

Merck to expand reagent production capacity in China

The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons

3M to invest nearly $150 million on expanding biopharma filtration capabilities

The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.

Evonik launches next-generation peptide for biopharma applications

One thousand times more soluble than L-cystine at neutral pH

AnaBios acquires Cell Systems to expand human cell portfolio for drug discovery